Efficacy and safety of olverembatinib in adult BCR::ABL1-positive ALL with T315I mutation or relapsed/refractory disease. Liu W, Wang C, Ouyang W, Hao J, et al. Br J Haematol 2024;205:2228-2233.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Liu W, Wang C, Ouyang W, Hao J, et al. Efficacy and safety of olverembatinib in adult BCR::ABL1-positive ALL with T315I mutation or relapsed/refractory disease. Br J Haematol 2024;205:2228-2233.
PMID: 39363594